Thank you!
Recruitment to the RIDD Trial is complete
Following a fantastic response from people with Dupuytren’s disease, recruitment to the RIDD trial is now complete and we are no longer seeking people to join the study. Thank you to everyone who enabled this to happen, those of you who got in touch about participating or supported us in other ways.
What happens next?
People who are part of the study will attend one of our research clinics for treatment and assessment. They are being followed up by the study team for 18 months from their first treatment. After the last person attends for their final study visit, we will be able to start analysing the data. We expect results from the study to be available in 2021.
Keep up to date with the Duputren's Trial by following us on our facebok page or Twitter Account.
We are working to shape the medical care of early stage Dupuytren's disease. Our research focuses on finding the first targeted therapy involving a simple injection for patients with the condition that will preserve hand function and avoid the need for subsequent more invasive treatments such as surgery.
Our research study called RIDD is a major part of this work. [Learn more]
We are no longer seeking people to join our research study but you can find details of other research studies running in the UK on the Be Part Of Research website. Enter ‘Dupuytren's’ into the ‘I’m looking for research about’ box.
04 May2020
NDORMS team have won the International Dupuytren Award 2020!
We are delighted to announce that for the second year running the NDORMS team have been chosen as the winner of the International Dupuytren Award 2020 for our publication of "Identification of TNFR2 and IL-33 as therapeutic targets in localized fibrosis" congratulations to David Izadi, Thomas Layton et al..
